New Drugs and Clinical Research · global
RAS inhibitor extends survival in pancreatic cancer; mRNA flu vaccine and new dermatomyositis drug approved in the US
From extending the lives of patients with advanced cancer to reducing reliance on steroids in autoimmune disease, three US approvals mark different forms of clinical progress. Beyond the efficacy figures, eligible populations and safety risks are equally important.
For patients with metastatic pancreatic cancer whose disease continues to progress despite treatment, additional survival time is the most direct value a new therapy can offer. On August 26, 2026, the US Food and Drug Administration (FDA) approved the RAS inhibitor daraxonrasib. In the randomized trial supporting approval, patients receiving this oral drug had a median overall survival of 13.2 months, compared with 6.7 months in the chemotherapy group. That same month, an mRNA flu vaccine and an oral drug for dermatomyositis also cleared regulatory hurdles, adding options for infection prevention and chronic disease treatment, respectively.
Daraxonrasib, marketed as Rasonque, acts on the RAS family of proteins involved in cell growth signaling. According to the FDA announcement, the approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are not candidates for multiagent systemic therapy. However, the main efficacy evidence comes from patients whose disease progressed after first-line systemic therapy. Interpreting the findings requires distinguishing the approved population from the trial’s actual eligibility criteria.
The open-label, multicenter trial, called RASolute 302, randomly assigned 500 patients to daraxonrasib or standard chemotherapy chosen by their physician. In addition to the improvement in overall survival, the median time without disease progression increased from 3.6 months to 7.2 months, while the objective tumor response rate rose from 11% to 30%. The hazard ratio for overall survival was 0.40, but this is a statistical comparison of the risk of death between the two groups during follow-up; it cannot be interpreted as every patient gaining a fixed amount of survival time. The drug’s warnings cover risks including gastrointestinal perforation and interstitial lung disease or pneumonitis, showing that gains in efficacy still come with toxicities that require management.
Another development came in flu prevention. On August 5, the FDA approved ModernaTX’s Mflusiva for adults aged 50 and older to prevent disease caused by the influenza A virus subtypes and influenza B viruses covered by the vaccine. According to a summary by 2 Minute Medicine, its large Phase 3 trial showed a relative vaccine efficacy advantage of 26.6% compared with a standard-dose flu vaccine; this does not mean protection increased by 26.6 percentage points. The report also noted more short-term reactions after vaccination, while a single trial cannot establish whether the advantage will persist across different flu seasons.
For dermatomyositis, Roivant announced on August 27, through a filing with the US Securities and Exchange Commission, that the FDA had approved once-daily, 30 mg Lisraya (brepocitinib) for adults. Dermatomyositis affects the muscles and skin, and patients may experience weakness, pain, and skin lesions at the same time. The new drug inhibits TYK2 and JAK1 signaling, and its clinical value includes both improving disease activity and whether it can reduce steroid use.
According to the VALOR trial results released by the company, by the end of 52 weeks of treatment, 55% of patients in the Lisraya group had achieved both at least moderate improvement and very low-dose or no steroid use, compared with 30% in the placebo group. Among patients initially taking at least 7.5 mg of steroids daily, measured in prednisone-equivalent doses, the proportions who discontinued steroids entirely were 45% and 29%, respectively. These results provide evidence of a steroid-sparing benefit, but the drug also carries a boxed warning for serious infections, death, malignancies, major adverse cardiovascular events, and thrombosis. Some of these warnings are based on studies of other JAK inhibitors in populations with different diseases and cannot be directly treated as the incidence of risks in this trial.
The three advances address different questions: whether a pancreatic cancer drug extends life, whether a vaccine reduces flu illness, and whether an immunomodulatory drug can improve symptoms and reduce the burden of steroid use. Approval creates an opportunity for these results to enter routine medical care, but the average benefits seen in trials, the risks borne by individual patients, and performance with longer-term use still need to be weighed separately.